USA - engelsk - NLM (National Library of Medicine)

xellia pharmaceuticals usa llc - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa . this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa. colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to treat or p

USA - engelsk - NLM (National Library of Medicine)

fresenius kabi usa, llc - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli.  it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa .  this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa . colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli.  to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to t

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - colistimethate sodium, quantity: 1 million iu - inhalation - excipient ingredients: - tadim powder for nebuliser solution is indicated for the treatment of colonisation and infections of the lung due to susceptible pseudomonas aeruginosa in patients with cystic fibrosis. consideration should be given to official guidance on the appropriate use of antibacterial agents.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - colistimethate sodium (equivalent: colistin, qty iu) - injection, powder for - excipient ingredients: - colistin link parental is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitve strains of pseudomonas aeruginosa. this antibiotic is not indicated for infections due to proteus and neisseria. colistin link parental has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa. pending results of appropriate bacterialogic cultures and sensitvity tests, colistin link parental may be used to initiate therapy in serious infections that are suspected due to gram-negative organisms.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - colistimethate sodium - powder for nebuliser solution - colistin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - colistimethate sodium - powder for nebuliser solution - colistin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - colistimethate sodium - powder for solution for injection/infusion - colistin

Irland - engelsk - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - colistimethate sodium - powder for solution for injection/infusion - colistin

USA - engelsk - NLM (National Library of Medicine)

paddock laboratories, llc - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistin 150 mg in 2 ml

USA - engelsk - NLM (National Library of Medicine)

x-gen pharmaceuticals, inc. - colistimethate (unii: dl2r53p963) (colistin - unii:z67x93hjg1) - colistin 150 mg in 2 ml - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa. this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa . colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to treat or